Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Five RNAi-Related Patent Applications: Feb 7, 2008

Premium
Title: Methods and Compositions for Use in Preparing Hairpin RNAs
 
Number: 20080021205
 
Filed: Dec. 10, 2004 PCT Filed: Dec. 10, 2004
 
Lead Inventor: Helen Blau, Stanford University
 
According to the patent application’s abstract, the invention comprises “methods and compositions for producing hRNA, e.g., shRNA, expression modules for specific target nucleic acids. … In the subject methods, an initial nucleic acid … corresponding to the target nucleic acid of interest is converted to an intermediate nucleic acid. The resultant intermediate nucleic acid, following an optional size modification step, is then converted to a linear dsDNA that includes at least one copy of the hRNA expression module of interest, or a precursor (i.e., pro-shRNA expression module) thereof, where in certain embodiments conversion may include amplification. Also provided are reagents, systems, and kits for use in practicing the subject methods.”
 

 
Title: Cell-Based RNA Interference and Related Methods and Compositions
 
Number: 20080025958
 
Filed: Nov. 21, 2006
 
Lead Inventor: Gregory Hannon, Cold Spring Harbor Laboratory
 
The invention, the patent application’s abstract states, comprises “barcoded shRNA libraries and methods of using same.”
 
The application specifically claims “a method for identifying a gene that affects the sensitivity of tumor cells to a chemotherapeutic agent … [by] introducing into a subject a plurality of transfected stem cells, wherein each transfected stem cell comprises a nucleic acid construct comprising a representative shRNA of a barcoded shRNA library, and wherein a representative shRNA of the barcoded shRNA library is complementary to at least a portion of a representative target gene.” The abstract notes that the plurality of transfected stem cells if the invention “exhibits decreased expression of a representative target gene and … gives rise to transfected tumor cells in vivo.”
 
The invention also involves “administering a chemotherapeutic agent and … identifying representative shRNAs that are enriched or depleted by treatment with the therapeutic agent,” according to the application.
 

 
Title: Methods and Compositions Involving microRNA
 
Number: 20080026951
 
Filed: Aug. 11, 2007
 
Lead Inventor: David Brown, Ambion (Applied Biosystems)
 
The invention, the patent application’s abstract states, “concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the … invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.”
 

 
Title: siRNA Targeting Vascular Endothelial Growth Factor
 
Number: 20080027215
 
Filed: July 23, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to VEGF.”
 

 
Title: siRNA Targeting Sodium Channel, Voltage-Gated, Type X, Alpha
 
Number: 20080027216
 
Filed: July 27, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
According to the patent application’s abstract, “efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to SCN10A.”

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.